{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002316","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.222729+00:00","generated_at":"2026-06-27T03:31:14.409743+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sutro FY2021 revenue $61.9M, operating expenses $160.4M; cash $229.5M; Tasly payment at risk","bullets":["Cash, equivalents and marketable securities $229.5M at Dec 31, 2021, down from $326.5M; runway into H2 2023.","Revenue $61.9M (up 45% from $42.7M) from Merck, BMS, EMD Serono collaborations.","Operating expenses $160.4M (up 41% from $113.8M); R&D $104.4M, G&A $56.0M.","STRO-002 Phase 1 dose-expansion enrollment completed Nov 2021; registrational study discussions expected mid-2022.","Tasly seeks to renegotiate STRO-002 Greater China terms; $40M initial payment uncertain; Sutro considering remedies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002316","json":"https://secwatch.observer/filing/0000950170-22-002316.json","markdown":"https://secwatch.observer/filing/0000950170-22-002316.md","text":"https://secwatch.observer/filing/0000950170-22-002316.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022002316/0000950170-22-002316-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022002316/stro-20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:31:14.409743+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}